Neovasc (NASDAQ:NVCN) Coverage Initiated by Analysts at

Equities research analysts at started coverage on shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) in a research report issued on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, Bloom Burton reaffirmed a “buy” rating on shares of Neovasc in a report on Friday, August 12th.

Neovasc Price Performance

Shares of NVCN stock opened at $7.42 on Friday. The company has a market capitalization of $20.35 million, a PE ratio of -0.62 and a beta of 2.22. The firm has a fifty day simple moving average of $6.98 and a 200-day simple moving average of $7.69. The company has a current ratio of 12.88, a quick ratio of 12.50 and a debt-to-equity ratio of 0.27. Neovasc has a twelve month low of $4.59 and a twelve month high of $21.47.

Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) last posted its quarterly earnings results on Thursday, August 11th. The medical equipment provider reported ($3.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($2.04). The company had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.60 million. Neovasc had a negative net margin of 1,114.01% and a negative return on equity of 59.00%. Equities research analysts anticipate that Neovasc will post -12.07 earnings per share for the current fiscal year.

About Neovasc

(Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

Featured Stories

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.